SCHEDULE 13G: Blue Owl Capital Holdings LP Discloses 5.18% Passive Stake in Marker Therapeutics, Inc.
Beneficial Ownership Disclosure
Blue Owl Capital Holdings LP has reported a passive 5.18% beneficial ownership stake in Marker Therapeutics, Inc. as of December 31, 2024.
Summary
- Blue Owl Capital Holdings LP (the "Reporting Person") has filed a Schedule 13G with the SEC.
- The filing indicates that Blue Owl Capital Holdings LP beneficially owns 554,250 shares of Common Stock in Marker Therapeutics, Inc.
- This ownership represents 5.18% of Marker Therapeutics, Inc.'s total outstanding common stock.
- The percentage is calculated based on 10,707,295 shares of common stock outstanding as of January 17, 2025, as reported by the Issuer.
- The Reporting Person holds sole voting power and sole dispositive power over all 554,250 shares.
- The shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing the control of Marker Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake, providing no explicit positive or negative performance indicators for the issuer.
Positives
- A significant institutional investor, Blue Owl Capital Holdings LP, has disclosed a passive stake, which may signal institutional confidence or interest in Marker Therapeutics, Inc.
Future Outlook
NA
Industry Context
This filing indicates an institutional investment in Marker Therapeutics, Inc., a company in the biotechnology sector. While the filing itself does not provide broader industry trends, it reflects continued institutional interest in companies within the biotech space.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake may provide a degree of confidence or signal institutional interest in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (end of reporting period). |
| 01/17/2025 | Date as of which 10,707,295 shares of common stock were outstanding, as reported in the Issuer's Prospectus. |
| 02/14/2025 | Date of filing the Schedule 13G. |
Keywords
Marker Therapeutics, Blue Owl Capital Holdings LP, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.